Skip to main content

Table 2 Response according to RECIST best overall response, by group

From: Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)

Category

GROUP 1:

Cohort 1

(RO6870810

0.30 mg/kg) +

Atezo

GROUP 1:

Cohort 2

(RO6870810

0.45 mg/kg) +

Atezo

GROUP 1:

Cohort 3

(RO6870810

0.65 mg/kg) +

Atezo

GROUP 2:

Cohort 1|

(run-in with RO6870810

0.30 mg/kg)

THEN

(RO6870810

0.30 mg/kg) +

Atezo

GROUP 2:

Cohort 2|

(run-in with RO6870810

0.45 mg/kg)

THEN

(RO6870810

0.45 mg/kg) +

Atezo

GROUP 3:

Expansion

Group

TNBC

GROUP 4:

Expansion

Group

OC

N

4

7

6

4

6

3

6

PR

1 (25%)

1 (14.3%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

SD

1 (25%)

2 (28.6%)

4 (66.7%)

1 (25%)

5 (83.3%)

2 (66.7%)

0 (0%)

PD

2 (50%)

3 (42.9%)

1 (16.7%)

3 (75%)

1 (16.7%)

0 (0%)

4 (66.7%)

Missing

0 (0%)

1 (14.3%)

1 (16.7%)

0 (0%)

0 (0%)

1 (33.3%)

2 (33.3%)

Responder

1 (25%)

1 (14.3%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

Non-Responder

3 (75%)

6 (85.7%)

6 (100%)

4 (100%)

6 (100%)

3 (100%)

6 (100%)

  1. Responder is defined as any subject who exhibits a complete response or partial response. Missing response is assumed as a non-responder